Persomed has partnered up with QbD, myNEO, VUB, and UZA to further persue its primary goal: bringing personalized cancer vaccines closer to every patient.
Together we aim to validate the current Persomed Tetramix-DC-NEO technology platform in a first clinical phase I study in mMSS-CRC patients and, in parallel, we will continue to strive to develop a robust automated and digitally supported workflow for personalized cancer vaccine production building on the expertise and interest of the different partners.
In June, the PSM-CRC project concept was successfully defended by Lien Lybaert, Martijn Reniers, Bert Coessens, Kris Thielemans and Timon Vandamme in front of the jury.
Last month the full proposal was submitted. The next and last hurdle will be the defense in front of the VLAIO jury beginning of November to hopefully receive approval by the end of this year.
Fingers crossed!